Pfizer stock jumps after it reports positive data in early-stage coronavirus vaccine trial

Pfizer stock jumps after it reports positive data in early-stage coronavirus vaccine trial


In this photo illustration the American multinational pharmaceutical corporation Pfizer logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.

Budrul Chukrut | SOPA Images | Getty Images

Pfizer shares jumped by nearly 7% in premarket trading Wednesday after it released positive results from its closely watched early-stage human trial on a coronavirus vaccine. 

The trial evaluated 45 people. Each participant received two doses of either 10, 30 or 100 micrograms of the vaccine or a placebo. 

The company coronavirus vaccine produced neutralizing antibodies, which researchers say is important for acquiring protection, in all participants who received the 10 or 30 microgram dose after 28 days, according to the preliminary data, which were posted in a paper released on MedRXiv.

“We are encouraged by the clinical data of BNT162b1, one of four mRNA constructs we are evaluating clinically, and for which we have positive, preliminary, topline findings,” Kathrin Jansen, head of Pfizer’s vaccine research and development, said in a press release. “We are dedicated to develop potentially groundbreaking vaccines and medicines, and in the face of this global health crisis, we approach this goal with the utmost urgency.”

The U.S.-based pharmaceutical giant has been working alongside German drugmaker BioNTech. The company’s experimental vaccine contains genetic material called messenger RNA, or mRNA. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response for the virus.

Pfizer said the vaccine was generally well-tolerated, though the experimental vaccine also caused fever in some patients, especially for those who were in the 100 microgram group. Most patients reported pain at the injection site, which was mild to moderate, the company said, except in one of 12 subjects who received a 100 microgram dose, which was severe.

The findings posted Wednesday have not been peer-reviewed yet. 

This is a developing story. Please check back for updates.


Source link